RBRXF — Rhino Biotech Share Price
Last trade - 00:00Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | n/a | ||
| Price to Tang. Book | n/a | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | n/a | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | n/a | ||
| Return on Equity | n/a | ||
| Operating Margin | n/a | ||
Financial Summary
| Year End 31st Dec | Unit | 2016 | 2017 | 2018 | 2019 | 2020 | 2021E | 2022E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Rhino Biotech Limited is focused on agricultural technology (agritech), biotechnology (biotech), biopharmaceutical (biopharma). The Company's divisions include Fortify RX, AGRITECH RHINO and BioOrganics. Its Fortify RX division produces, manufactures, and distributes cannabis-derived cannabinoids and other natural compounds for use in nutraceuticals and pharmaceuticals as well as health and wellness products. Its AGRITECH RHINO division is engaged in improving plant and fungus genetics through cloning and hybridization technology. Its BioOrganics division is engaged in research and development; preventing contamination and deterioration and extending the lifespan and efficacy of organic compounds.
Directors
- Last Annual
- December 31st, 2020
- Last Interim
- December 31st, 2007
- Incorporated
- December 31st, 2007
- Public Since
- December 6th, 2004
- Sector
- Food & Tobacco
- Industry
- Consumer Defensives
- Exchange
- Pink Sheets on Nasdaq
- Shares in Issue
- 31,048,368
- Address
- 294 Heywood House, British West Indies
- Web
- https://rhinobiotech.com/
- Phone
- Auditors
- Davidson & Co LLP
Similar to RBRXF
Adia Nutrition
Pink Sheets on Nasdaq
African Agriculture Holdings
Pink Sheets on Nasdaq
Agri-Dynamics
Pink Sheets on Nasdaq
Agristar
Pink Sheets on Nasdaq
Aifarm
Pink Sheets on Nasdaq
FAQ
As of Today at 21:55 UTC, shares in Rhino Biotech are trading at $0.00. This share price information is delayed by 15 minutes.
Shares in Rhino Biotech last closed at $0.00 and the price had moved by over the past 365 days. In terms of relative price strength the Rhino Biotech share price has underperformed the S&P500 Index by -9.85% over the past year.
There is no consensus recommendation for this security.
Find out moreRhino Biotech does not currently pay a dividend.
Rhino Biotech does not currently pay a dividend.
Rhino Biotech does not currently pay a dividend.
To buy shares in Rhino Biotech you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of $0.00, shares in Rhino Biotech had a market capitalisation of .
Here are the trading details for Rhino Biotech:
- Country of listing: United States
- Exchange: PNK
- Ticker Symbol: RBRXF
Based on an overall assessment of its quality, value and momentum Rhino Biotech is currently classified as a . The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
We could not find analyst target price data for this security.
Find out moreAn important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Rhino Biotech. Over the past six months, its share price has outperformed the S&P500 Index by +9661.02%.
As of the last closing price of $0.00, shares in Rhino Biotech were trading matched their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Rhino Biotech PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $0.00.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Rhino Biotech's management team is headed by:
- Nicholas Baxter - PRE
- Graham Crabtree - CFO
- Stephen Kenwood - IND